Business Context and Reporting Period
Company: Glaukos Corporation (GKOS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2024
Business Overview: Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing dropless platform therapies for glaucoma, corneal disorders, and retinal diseases. Key products include the iStent family of devices, Photrexa for keratoconus, and the recently commercialized iDose TR procedural pharmaceutical.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6 Months 2024 | 6 Months 2023 |
|---|---|---|---|---|
| Net Sales | $95,690 | $80,399 | $181,312 | $154,298 |
| Gross Profit | $73,140 | $60,296 | $138,504 | $116,124 |
| Gross Margin | 76% | 75% | 76% | 75% |
| Operating Expenses | $103,114 | $89,371 | $207,544 | $178,192 |
| Loss from Operations | $(29,974) | $(29,075) | $(69,040) | $(62,068) |
| Net Loss | $(50,545) | $(32,812) | $(91,383) | $(67,438) |
| Diluted Net Loss Per Share | $(1.00) | $(0.68) | $(1.82) | $(1.40) |
| Cash & Equivalents | $68,075 | $93,467 | As of June 30, 2024 | |
| Short-term Investments | $193,589 | $201,964 | As of June 30, 2024 | |
| Total Liquidity (Cash + ST Inv + Restricted) | $266,397 (As of June 30, 2024) | |||
| Convertible Senior Notes (Principal) | $57,500 (As of June 30, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 19% in Q2 2024 and 18% for the six months ended June 30, 2024, compared to the prior year periods. Growth was driven by higher volumes of iStent family products (specifically iStent infinite) and early contributions from iDose TR.
- Convertible Note Exchange: In June 2024, the Company repurchased $230.0 million in principal amount of its 2.75% Convertible Senior Notes due 2027. This was settled via the issuance of approximately 4.25 million shares of common stock and cash for accrued interest. This transaction resulted in a non-cash inducement charge of $17.4 million and reduced the remaining debt principal to $57.5 million.
- Operating Expenses: Total operating expenses increased 15% in Q2 and 16% for the six months, primarily due to increased SG&A (compensation, commercial infrastructure) and Acquired In-Process R&D (IPR&D) expenses related to new license agreements and asset acquisitions.
- Net Loss Expansion: Net loss increased 54% in Q2 and 36% for the six months, largely attributable to the $18.0 million in charges associated with the convertible note exchange and increased operating costs.
Guidance, Outlook, and Risks
- Commercialization of iDose TR: The Company began commercializing iDose TR in February 2024. Success depends on physician adoption, manufacturing capacity, and reimbursement coverage. A permanent J-code (J7355) was assigned by CMS effective July 1, 2024.
- Reimbursement Environment: CMS 2024 Final Rule increased facility fee rates for iStent infinite standalone procedures but maintained lower physician fee rates for combo procedures, which may continue to impact volumes. International sales were modestly affected by unfavorable foreign exchange rates (notably Japanese Yen).
- Liquidity: The Company maintains approximately $266 million in cash, cash equivalents, and short-term investments. Management believes this is sufficient to fund operations for at least the next 12 months.
- Convertible Note Conversion: As of June 30, 2024, the trading price of common stock met conditions allowing holders to convert the remaining $57.5 million of Convertible Notes between July 1 and September 30, 2024. Conversion could require cash settlement, potentially impacting liquidity.
- Risks: Key risks include the commercial success of iDose TR, supply chain disruptions, regulatory changes affecting reimbursement, and the potential for future debt service obligations or equity dilution.
Investor Verification Checklist
- Debt Conversion Terms: Verify the specific settlement terms (cash vs. stock) for the remaining $57.5 million Convertible Notes if conversion is triggered in Q3 2024.
- iDose TR Adoption: Monitor early sales data and reimbursement rates for iDose TR following the July 1, 2024 J-code implementation.
- Reimbursement Policy Changes: Track final Local Coverage Determinations (LCDs) from Medicare Administrative Contractors (MACs) regarding iStent infinite and iDose TR procedures.
- Operating Leverage: Assess whether SG&A growth will stabilize as revenue scales, given the 25% increase in SG&A in Q2 2024.
- Inventory Levels: Review inventory buildup ($56.5 million as of June 30, 2024) to ensure it aligns with demand forecasts for new product launches.